• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI
Sep 27 2018
2

Cardax CEO Featured on Big Biz TV Show

By Cardax | Management Insights, Media Mentions | No Comments
Cardax CEO, David G. Watumull, was featured Friday, September 21, 2018, on the business television and radio show, The Big Biz Show. The show is simulcast on television and radio...
Read More

About Cardax

Cardax is developing astaxanthin therapies for large unmet medical needs where inflammation and oxidative stress play key causative roles. Learn more >>

Recent News

  • Cardax Reports Q3 2020 Results November 13, 2020
  • Cardax Reports Q2 2020 Results August 14, 2020
  • Cardax Reports Q1 2020 Results May 15, 2020
  • Cardax Reports 2019 Annual Results March 30, 2020
Subscribe to Receive Updates by E-Mail Cardax News Alerts

Recent News

  • Cardax Reports Q3 2020 Results November 13, 2020
  • Cardax Reports Q2 2020 Results August 14, 2020
  • Cardax Reports Q1 2020 Results May 15, 2020

© 2020 Cardax, Inc. | Disclaimer and Terms of Use

  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Investors
  • News
  • Subscribe